Bank Julius Baer & Co. Ltd Zurich Acquires 17,469 Shares of Bruker Co. (NASDAQ:BRKR)

Bank Julius Baer & Co. Ltd Zurich lifted its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 14.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 141,890 shares of the medical research company's stock after buying an additional 17,469 shares during the period. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.09% of Bruker worth $8,379,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in BRKR. True Wealth Design LLC increased its position in shares of Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock worth $36,000 after purchasing an additional 510 shares during the period. Eagle Bay Advisors LLC grew its stake in Bruker by 2,324.1% during the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock worth $41,000 after buying an additional 674 shares in the last quarter. UMB Bank n.a. increased its holdings in Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock valued at $53,000 after buying an additional 248 shares during the period. GAMMA Investing LLC raised its position in shares of Bruker by 47.5% in the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after buying an additional 412 shares in the last quarter. Finally, Capital Performance Advisors LLP bought a new stake in shares of Bruker during the 3rd quarter worth approximately $77,000. Institutional investors and hedge funds own 79.52% of the company's stock.

Remove Ads

Bruker Stock Up 0.4 %

NASDAQ:BRKR traded up $0.19 on Wednesday, hitting $45.75. The stock had a trading volume of 217,384 shares, compared to its average volume of 1,260,451. Bruker Co. has a 52 week low of $44.89 and a 52 week high of $94.86. The business's fifty day moving average is $54.48 and its 200 day moving average is $58.76. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The company has a market cap of $6.94 billion, a PE ratio of 60.19, a P/E/G ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, equities research analysts expect that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 annualized dividend and a dividend yield of 0.44%. Bruker's payout ratio is 26.32%.

Analyst Ratings Changes

Several research firms have weighed in on BRKR. Guggenheim restated a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Stifel Nicolaus decreased their target price on Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research report on Friday, February 14th. Barclays reduced their price target on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Bank of America boosted their price target on shares of Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. Finally, UBS Group initiated coverage on shares of Bruker in a research report on Tuesday, December 10th. They set a "neutral" rating and a $66.00 price target on the stock. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Bruker has an average rating of "Moderate Buy" and a consensus price target of $70.50.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.